FI4015527T3 - Rekombinantti fsh, joka sisältää alfa-2,3- ja alfa-2,6-sialylaation - Google Patents

Rekombinantti fsh, joka sisältää alfa-2,3- ja alfa-2,6-sialylaation Download PDF

Info

Publication number
FI4015527T3
FI4015527T3 FIEP21212873.0T FI21212873T FI4015527T3 FI 4015527 T3 FI4015527 T3 FI 4015527T3 FI 21212873 T FI21212873 T FI 21212873T FI 4015527 T3 FI4015527 T3 FI 4015527T3
Authority
FI
Finland
Prior art keywords
alpha
sialylation
recombinant fsh
fsh including
pharmaceutical composition
Prior art date
Application number
FIEP21212873.0T
Other languages
English (en)
Finnish (fi)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI4015527(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of FI4015527T3 publication Critical patent/FI4015527T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FIEP21212873.0T 2008-04-16 2009-04-16 Rekombinantti fsh, joka sisältää alfa-2,3- ja alfa-2,6-sialylaation FI4015527T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25

Publications (1)

Publication Number Publication Date
FI4015527T3 true FI4015527T3 (fi) 2025-04-29

Family

ID=39717519

Family Applications (4)

Application Number Title Priority Date Filing Date
FIEP21212873.0T FI4015527T3 (fi) 2008-04-16 2009-04-16 Rekombinantti fsh, joka sisältää alfa-2,3- ja alfa-2,6-sialylaation
FIEP16179121.5T FI3098234T3 (fi) 2008-04-16 2009-04-16 Alfa-2,3- ja alfa-2,6-sialylaation sisältävä rekombinantti-fsh
FIC20250003C FIC20250003I1 (fi) 2008-04-16 2025-01-15 Follitropiini delta
FIC20250025C FIC20250025I1 (fi) 2008-04-16 2025-07-11 Follitropiini delta

Family Applications After (3)

Application Number Title Priority Date Filing Date
FIEP16179121.5T FI3098234T3 (fi) 2008-04-16 2009-04-16 Alfa-2,3- ja alfa-2,6-sialylaation sisältävä rekombinantti-fsh
FIC20250003C FIC20250003I1 (fi) 2008-04-16 2025-01-15 Follitropiini delta
FIC20250025C FIC20250025I1 (fi) 2008-04-16 2025-07-11 Follitropiini delta

Country Status (29)

Country Link
US (7) US8951967B2 (cg-RX-API-DMAC7.html)
EP (7) EP3098234B1 (cg-RX-API-DMAC7.html)
JP (7) JP2011519359A (cg-RX-API-DMAC7.html)
KR (5) KR102108377B1 (cg-RX-API-DMAC7.html)
CN (3) CN105906703A (cg-RX-API-DMAC7.html)
AR (1) AR071479A1 (cg-RX-API-DMAC7.html)
AU (5) AU2009237479B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0910461B8 (cg-RX-API-DMAC7.html)
CA (1) CA2725257A1 (cg-RX-API-DMAC7.html)
CY (1) CY1115413T1 (cg-RX-API-DMAC7.html)
DK (6) DK3098234T3 (cg-RX-API-DMAC7.html)
ES (5) ES2989729T3 (cg-RX-API-DMAC7.html)
FI (4) FI4015527T3 (cg-RX-API-DMAC7.html)
FR (3) FR17C1020I2 (cg-RX-API-DMAC7.html)
HR (5) HRP20241187T1 (cg-RX-API-DMAC7.html)
HU (9) HUE033830T2 (cg-RX-API-DMAC7.html)
IL (2) IL208538A (cg-RX-API-DMAC7.html)
LT (8) LT3045471T (cg-RX-API-DMAC7.html)
MX (3) MX348622B (cg-RX-API-DMAC7.html)
NO (4) NO2017025I1 (cg-RX-API-DMAC7.html)
NZ (1) NZ588381A (cg-RX-API-DMAC7.html)
PL (6) PL2808340T3 (cg-RX-API-DMAC7.html)
PT (6) PT3144318T (cg-RX-API-DMAC7.html)
RU (3) RU2682270C2 (cg-RX-API-DMAC7.html)
SA (1) SA109300228B1 (cg-RX-API-DMAC7.html)
SI (6) SI2808340T1 (cg-RX-API-DMAC7.html)
TW (1) TWI488640B (cg-RX-API-DMAC7.html)
WO (1) WO2009127826A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007373B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
CN103154243A (zh) 2010-10-15 2013-06-12 日本化学研究株式会社 糖链的非还原末端为甘露糖残基的糖蛋白的制造方法
CA3163525A1 (en) 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
JP6279466B2 (ja) * 2012-04-27 2018-02-14 Jcrファーマ株式会社 新規な発現ベクター
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) * 2014-05-31 2020-02-19 Jcrファーマ株式会社 ウリジンとn−アセチル−d−マンノサミンとを含有する培地
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Cmp依存性シアリダーゼ活性
HUE054300T2 (hu) 2015-04-17 2021-08-30 Ferring Bv FSH-t tartalmazó, meddõség kezelésére szolgáló készítmény
US10906953B2 (en) 2015-06-26 2021-02-02 Ferring B.V. Methods of purification and/or viral inactivation
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
SI3973982T1 (sl) 2017-09-01 2024-10-30 Ferring B. V. Sestavek za nadzorovano stimulacijo jajčnikov
WO2019211153A1 (en) 2018-04-30 2019-11-07 Ferring B.V. Composition for controlled ovarian stimulation
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
CN118922201A (zh) 2022-04-01 2024-11-08 辉凌公司 治疗不育症的混合方案
KR20250016113A (ko) 2022-05-26 2025-02-03 훼링 비.브이. 남성 불임 치료를 위한 조성물 및 방법
MA71382A (fr) 2022-07-08 2025-04-30 Ferring B.V. Compositions et procédés d'insémination intra-utérine (iiu)
KR20260041113A (ko) 2023-07-20 2026-03-26 훼링 비.브이. 서방형의 약물-로딩된 마이크로입자

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
AU736993B2 (en) 1997-01-16 2001-08-09 Novo Nordisk A/S Practical in vitro sialylation of recombinant glycoproteins
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
CA2372714A1 (en) 1999-05-07 2000-11-16 Stephen Franks The use of luteinizing hormone in the induction of pauci-or unifolliculogenesis
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
IL161235A0 (en) * 2001-10-22 2004-09-27 Applied Research Systems Fsh composition, its preparation and use
EA008220B1 (ru) 2001-10-29 2007-04-27 Круселл Холланд Б.В. Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения
ATE384785T1 (de) 2001-12-07 2008-02-15 Crucell Holland Bv Herstellung von viren, virusisolaten, und impfstoffen
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1694351A2 (en) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
ATE476666T1 (de) 2004-02-04 2010-08-15 Centre Nat Rech Scient Verfahren zur identifizierung von glykoformspezifischen antikörpern
CA2557725C (en) 2004-02-13 2015-06-30 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
US8790322B2 (en) 2010-08-03 2014-07-29 King Saud University Stoma coat
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
CA3163525A1 (en) 2011-03-31 2012-10-04 Ferring Bv. Pharmaceutical preparation
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AR100132A1 (es) 2014-04-18 2016-09-14 Glycotope Gmbh Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino

Also Published As

Publication number Publication date
EP2268666A1 (en) 2011-01-05
SI3045471T1 (sl) 2017-07-31
KR20110005863A (ko) 2011-01-19
LT2808340T (lt) 2016-11-10
HRP20170958T1 (hr) 2017-09-22
PL3098234T3 (pl) 2025-01-07
JP2011519359A (ja) 2011-07-07
HUS2500029I1 (hu) 2025-07-28
FI3098234T3 (fi) 2024-10-31
EP3045471B1 (en) 2017-03-29
LT3098234T (lt) 2024-09-10
RU2745557C1 (ru) 2021-03-29
US20110105398A1 (en) 2011-05-05
JP6762916B2 (ja) 2020-09-30
CA2725257A1 (en) 2009-10-22
DK4015527T3 (da) 2025-04-14
SI3144318T1 (sl) 2020-12-31
ES2629392T3 (es) 2017-08-09
SI4015527T1 (sl) 2025-05-30
AU2017204258A1 (en) 2017-07-20
US9546204B2 (en) 2017-01-17
FR25C1025I1 (fr) 2025-09-19
EP3098234B1 (en) 2024-07-31
NO2025006I1 (no) 2025-01-16
HUE068565T2 (hu) 2025-01-28
US11952407B2 (en) 2024-04-09
AU2014203277C1 (en) 2017-07-27
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
CY1115413T1 (el) 2017-01-04
NO2017025I1 (no) 2017-06-06
JP2017060476A (ja) 2017-03-30
HUS1700025I1 (hu) 2017-06-28
AU2014203277B2 (en) 2017-04-06
WO2009127826A1 (en) 2009-10-22
PT4015527T (pt) 2025-04-10
NO2025032I1 (no) 2025-07-14
EP3144318A1 (en) 2017-03-22
RU2745557C3 (ru) 2021-12-10
SI2808340T1 (sl) 2016-12-30
SI2268666T1 (sl) 2014-07-31
PT2808340T (pt) 2016-11-21
RU2537268C2 (ru) 2014-12-27
BRPI0910461A8 (pt) 2018-10-16
KR101622944B1 (ko) 2016-05-23
PL3045471T3 (pl) 2017-10-31
EP3045471A1 (en) 2016-07-20
LT3045471T (lt) 2017-07-10
US20150065695A1 (en) 2015-03-05
CN105906703A (zh) 2016-08-31
ES3023526T3 (en) 2025-06-02
PL2268666T3 (pl) 2014-08-29
FR17C1020I1 (cg-RX-API-DMAC7.html) 2020-04-10
HUE033830T2 (en) 2018-01-29
US20180079794A1 (en) 2018-03-22
HUE030652T2 (en) 2017-05-29
DK3098234T3 (da) 2024-10-21
JP6486310B2 (ja) 2019-03-20
US20240327487A1 (en) 2024-10-03
PT3045471T (pt) 2017-06-14
KR102108377B1 (ko) 2020-05-08
BRPI0910461A2 (pt) 2018-03-27
HUS2500008I1 (hu) 2025-02-28
KR20180095140A (ko) 2018-08-24
PT3144318T (pt) 2020-11-04
US9771407B2 (en) 2017-09-26
AU2017225020A1 (en) 2017-09-28
EP4015527B1 (en) 2025-01-22
FIC20250025I1 (fi) 2025-07-11
EP3098234A1 (en) 2016-11-30
JP7316905B2 (ja) 2023-07-28
AU2017225020B2 (en) 2019-11-14
LTPA2017018I1 (lt) 2017-06-26
ZA201007373B (en) 2011-06-29
FR17C1020I2 (fr) 2020-04-10
FIC20250003I1 (fi) 2025-01-15
US20210332099A1 (en) 2021-10-28
US10995128B2 (en) 2021-05-04
RU2014141994A (ru) 2016-05-10
JP2024038000A (ja) 2024-03-19
SI3098234T1 (sl) 2024-10-30
US8951967B2 (en) 2015-02-10
PT3098234T (pt) 2024-10-21
TW200948378A (en) 2009-12-01
RU2010141908A (ru) 2012-05-27
IL208538A (en) 2014-03-31
KR20160056960A (ko) 2016-05-20
AR071479A1 (es) 2010-06-23
HRP20241187T1 (hr) 2024-12-06
MX348622B (es) 2017-06-22
HUS1700036I1 (hu) 2017-10-30
JP2015120696A (ja) 2015-07-02
DK2268666T3 (da) 2014-05-12
TWI488640B (zh) 2015-06-21
BRPI0910461B8 (pt) 2021-05-25
CN102066414A (zh) 2011-05-18
US12516094B2 (en) 2026-01-06
FR25C1003I1 (fr) 2025-02-28
RU2014141994A3 (cg-RX-API-DMAC7.html) 2018-05-28
ES2468318T3 (es) 2014-06-16
AU2009237479A1 (en) 2009-10-22
US20160347811A1 (en) 2016-12-01
AU2017204259B2 (en) 2017-08-17
IL230571A (en) 2015-11-30
BRPI0910461B1 (pt) 2021-02-23
JP2020040956A (ja) 2020-03-19
HUE071059T2 (hu) 2025-07-28
KR20190092608A (ko) 2019-08-07
ES2989729T3 (es) 2024-11-27
DK2808340T3 (en) 2016-12-05
AU2017204259A1 (en) 2017-07-20
NO2017050I1 (no) 2017-09-28
LT4015527T (lt) 2025-04-10
EP2808340A1 (en) 2014-12-03
IL208538A0 (en) 2010-12-30
PL2808340T3 (pl) 2017-02-28
PL3144318T3 (pl) 2021-02-08
HRP20161520T1 (hr) 2016-12-30
RU2682270C2 (ru) 2019-03-18
HUE030652T4 (en) 2017-09-28
HRP20250313T1 (hr) 2025-05-09
HK1146284A1 (en) 2011-05-20
LTPA2017029I1 (lt) 2017-10-10
EP2268666B1 (en) 2014-03-12
LTPA2025505I1 (cg-RX-API-DMAC7.html) 2025-02-10
AU2017204258B2 (en) 2017-08-17
HK1199039A1 (en) 2015-06-19
KR20170110741A (ko) 2017-10-11
JP2018021037A (ja) 2018-02-08
DK3144318T3 (da) 2020-12-07
JP2022031652A (ja) 2022-02-22
US20260217782A1 (en) 2026-07-30
AU2009237479B2 (en) 2014-05-15
CN105906702A (zh) 2016-08-31
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
AU2014203277A1 (en) 2014-07-24
SA109300228B1 (ar) 2014-04-08
EP3144318B1 (en) 2020-09-23
NZ588381A (en) 2012-05-25
MX355457B (es) 2018-04-19
PT2268666E (pt) 2014-06-25
HUS1700024I1 (hu) 2017-06-28
DK3045471T3 (en) 2017-06-26
EP2808340B1 (en) 2016-08-17
LTPA2025525I1 (cg-RX-API-DMAC7.html) 2025-07-25
EP4015527A1 (en) 2022-06-22
EP2722339A1 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
HRP20161520T1 (hr) Rekombinantni fsh uključujući alfa 2,3- i alfa 2,6-sialilaciju
JP2018021037A5 (cg-RX-API-DMAC7.html)
CL2007002866A1 (es) Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
ME03089B (me) 1' -supstituisani karba-nukleozidni analozi za antivirusnu terapiju
CL2011000249A1 (es) Compuestos derivados de 2-[1-sustituido-1h-pirazolo[3,4-d]pirimidin-4-il](tio, oxi o amino)-n-(heteroaril)-alcanoamidas; con actividada moduladora de glucoquinasa glk o gk; composicion farmaceutica que comprende y uso en el tratamiento de la diabetes tipo 2 y obesidad.
CL2008002111A1 (es) Compuestos derivados de piridona, agonistas del receptor acoplado a proteina g gpr119; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico, cancer, entre otras.
MX339255B (es) Una para usarse en el rejuvenecimiento de la piel que comprende, eosina y , un oxidante y un factor cicatrizante.
SI2142186T1 (sl) Uporaba oligomerov mlečne kisline pri zdravljenju ginekoloških infekcij
IL218989A (en) Processed 3-phenylpropionic acids, their process, their preparations and their use
MX343360B (es) Conjugados peptidicos de agonistas del receptor de glp-1 y gastrina y su uso.
IL198142A0 (en) Benzoyl amino heterocyclyl compounds useful in the treatment of a disease mediated through glk
SI2432798T1 (sl) Derivat 17-hidroksi-17-pentafluoretil-estra-4,9(10)-dien-11-arila, postopki izdelave in uporaba pri zdravljenju bolezni
EA201101191A1 (ru) Фармацевтическая композиция, включающая ингибитор sglt-2, ингибитор дпп-iv и необязательно другой антидиабетический агент, и ее применение
AR096438A1 (es) Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
EA201491934A1 (ru) Аналоги глюкагоноподобного пептида-2 (glp-2)
EP2669269A3 (en) Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
IL212568A (en) Annotated 4,1-Diazepan, Pharmaceutical Preparations Containing Them and Their Uses in the Preparation of Medicines for the Treatment of Diseases or Disorders of Mammals
PL2401263T3 (pl) Podstawione pochodne azotu, zawierająca pochodne kompozycja farmaceutyczna, i sposób leczenia choroby Parkinsona przy ich użyciu
BRPI0809995A2 (pt) Composição, e, métodos para a liberação prolongada de um peptídeo em um paciente e para melhorar um sintoma associado com uma infecção por hiv
JP2010001264A5 (cg-RX-API-DMAC7.html)
SI2247369T1 (sl) Struktura katalizatorja titanovega dioksida za postpoke do 1000 C in njegova izdelava
NZ590469A (en) Treatment of rheumatoid arthritis with human beta defensins (1-4)
JP2008531710A5 (cg-RX-API-DMAC7.html)
LT2007416T (lt) Paratiroidinis hormonas (pth), skirtas naudoti išemijos gydymui
EP2546069A4 (en) PRINTING METHOD AND PRINTING AIDS USED THEREOF